CORCEPT THERAPEUTICS INC Quarterly Debt-to-equity in % from Q3 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Corcept Therapeutics Inc quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2024.
  • Corcept Therapeutics Inc Debt-to-equity for the quarter ending September 30, 2024 was 21.3 %, a 0.43% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 21.3 +0.09 +0.43% Sep 30, 2024
Q2 2024 22.4 +5.14 +29.8% Jun 30, 2024
Q1 2024 23.7 +9.07 +62.2% Mar 31, 2024
Q4 2023 22.8 +8.82 +62.9% Dec 31, 2023
Q3 2023 21.2 +8.09 +61.9% Sep 30, 2023
Q2 2023 17.3 +5.53 +47.1% Jun 30, 2023
Q1 2023 14.6 +3.78 +35% Mar 31, 2023
Q4 2022 14 +4.76 +51.4% Dec 31, 2022
Q3 2022 13.1 +4.45 +51.6% Sep 30, 2022
Q2 2022 11.8 +2.94 +33.4% Jun 30, 2022
Q1 2022 10.8 +1.76 +19.5% Mar 31, 2022
Q4 2021 9.26 +0.04 +0.43% Dec 31, 2021
Q3 2021 8.63 -0.98 -10.2% Sep 30, 2021
Q2 2021 8.81 -1 -10.2% Jun 30, 2021
Q1 2021 9.03 -0.91 -9.16% Mar 31, 2021
Q4 2020 9.22 -1.55 -14.4% Dec 31, 2020
Q3 2020 9.61 -1.57 -14% Sep 30, 2020
Q2 2020 9.81 Jun 30, 2020
Q1 2020 9.94 Mar 31, 2020
Q4 2019 10.8 Dec 31, 2019
Q3 2019 11.2 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.